GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP: A Phase II Study Toward Preventing Edema After Ischemia (I11.006)

Conclusions:RP-1127 was safe but the trial did not meet the primary efficacy outcome. Among patients with large hemispheric stroke at risk for cerebral edema, RP-1127 may reduce mortality and midline shift. Further prospective study is warranted to confirm these findings.Disclosure: Dr. Sheth has nothing to disclose. Dr. Elm has received research support from Remedy. Dr. Hinson has nothing to disclose. Dr. Molyneaux has nothing to disclose. Dr. Beslow has nothing to disclose. Dr. Sze has received research support from Remedy. Dr. Ostwaldt has received research support from Remedy. Dr. Del Zoppo has received research support from Remedy. Dr. Simard has received royalty payments from Remedy. Dr. Jacobson holds stock and/or stock options in Remedy. Dr. Kimberly has received research support from Remedy Pharmaceuticals, Inc.

Source: Neurology - April 3, 2016 Category: Neurology Authors: Sheth, K., Elm, J., Hinson, H., Molyneaux, B., Beslow, L., Sze, G., Ostwaldt, A.-C., Del Zoppo, G., Simard, J., Jacobson, S., Kimberly, W. Tags: Neurocritical Care and Neuroscience Crossroads: From Bench To Bedside Data Blitz Presentations Source Type: research